TIRZEPATIDE for Superior Glycemic Control & Maximum Treatment Success

The chart summarizes the results of the SURPASS-2 study, which compared the effectiveness of Tirzepatide (in various doses) to Semaglutide 1 mg in type 2 diabetes. Key findings: Tirzepatide at all doses (5 mg, 10 mg, and 15 mg) demonstrated significantly greater HbA1c reduction compared to Semaglutide 1 mg. Tirzepatide 15 mg can reduce HbA1c up to 2.3% A higher percentage of patients achieved HbA1c goal of 7% with Tirzepatide compared to Semaglutide. Up to 86% diabetic patients achieved the HbA1c goal with Tirzepatide within 40 weeks. This indicates that Tirzepatide might be a more effective treatment option for achieving better glycemic control in patients with type 2 diabetes.